Explore All 557 Venture Life Science Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | January 1, 2007 |
| Target | NextWave Pharmaceuticals |
| Sector | Life Science |
| Investor(s) |
Bay City Capital
Aisling Capital Eight Roads |
| Deal Type | Venture |
FILTER BY
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| Deal Context for Investor | # |
|---|---|
| Overall | 43 of 75 |
| Sector: Life Science | 29 of 54 |
| Type: Venture | 31 of 49 |
| State: California | 21 of 41 |
| Country: United States | 41 of 72 |
| Year: 2007 | 1 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-11-15 |
IDEV Technologies
Webster, Texas, United States IDEV Technologies is provider of medical devices for use in interventional radiology, vascular surgery, and cardiology. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-02-01 |
Syntonix Pharmaceuticals
Waltham, Massachusetts, United States Syntonix Pharmaceuticals, Inc. is a needle-free drug delivery company utilizing the FcRn receptor to transport macromolecules across epithelial barriers in the central airway and into circulation. |
Sell | $120M |
| Category | Private Equity Firm |
|---|---|
| Founded | 2000 |
| PE ASSETS | 1.8B USD |
| Size | Large |
| Type | Sector Focused |
Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.
| Deal Context for Investor | # |
|---|---|
| Overall | 9 of 56 |
| Sector: Life Science | 8 of 42 |
| Type: Venture | 6 of 29 |
| State: California | 2 of 15 |
| Country: United States | 9 of 52 |
| Year: 2007 | 2 of 8 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-01 |
ADMA Biologics
Ramsey, New Jersey, United States ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of Immune Deficiencies and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. ADMA Biologics was founded in 2004 and is based in Ramsey, New Jersey. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-25 |
Catalent
Somerset, New Jersey, United States Catalent is a provider of solutions for drugs, biologics and consumer health products. Among its core offerings, it develops and manufactures oral and sterile medication in nearly all dosage forms, holds patents for softgel (e.g. “Liqui-Caps” and “Vegicaps”) and Zydis fast-dissolve technologies used in many popular prescription and over-the-counter medicine. Catalent was founded in 2007 and is based in Somerset, New Jersey. |
Buy | $3.3B |
| Category | Private Equity Firm |
|---|---|
| Founded | 1969 |
| PE ASSETS | 11.0B USD |
| Size | Mega |
| Type | Sector Focused |
Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.
| Deal Context for Investor | # |
|---|---|
| Overall | 10 of 293 |
| Sector: Life Science | 4 of 73 |
| Type: Venture | 7 of 266 |
| State: California | 1 of 42 |
| Country: United States | 4 of 119 |
| Year: 2007 | 5 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-01 |
Optegra
London, United Kingdom Optegra is an eye healthcare provider treating A-Z eye conditions that is supported by dedicated optometrists, healthcare technicians and consultants who provide a wide range of procedures including lens replacement (Clarivu), laser eye surgery, cataract removal, glaucoma, and AMD. Optegra was founded in 2007 and is based in London, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-02-01 |
WuXi AppTec
Shanghai, China WuXi AppTec is a provider of pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec was founded in 2000 and is based in Shanghai, China. |
Buy | - |
